Konzon Pharma

Konzon Pharma is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of biologics for ophthalmic conditions. The company's primary focus is on addressing retinal vascular diseases through its lead candidate, KZ-001, a recombinant humanized anti-VEGF monoclonal antibody. Currently in Phase 3 clinical trials for neovascular age-related macular degeneration, KZ-001 represents the company's commitment to providing high-quality, accessible treatments for vision loss. Konzon maintains integrated R&D and manufacturing facilities to support its pipeline of innovative antibodies and biosimilars. The company is backed by prominent venture capital firms and continues to expand its therapeutic reach within the ophthalmology space.